Chief Executive – Nov. 15
Story has served as the independent lead director for Raymond James Financial, Inc., serves on the board of directors of Dominion Resources, Inc. and is on the board of the Moffitt Cancer Center and Research Institute Board of Advisors.
Clinical Oncology News – Nov. 15
Investigators at Moffitt Cancer Center, in Tampa, Fla., and several other institutions conducted a systematic review and meta-analysis to compare the effectiveness and toxicity of R-CHOP14 and R-CHOP21.
Stanford Medicine – Nov. 15
Maura Gillison, MD, PhD, professor of thoracic/head and neck medical oncology at MD Anderson Cancer Center in Houston, and Andy Trotti, MD, a professor of radiation oncology at Moffitt Cancer Center in Florida, share lead authorship.
Medical Xpress – Nov. 15
Researchers, led by Professor Alberto Chiappori (MD) from the Moffitt Cancer Center, Tampa, USA, wanted to investigate whether the combination of these two immunotherapies might be more effective against non-small cell lung cancer than either drug on its own. Also posted to Bioengineer.org and eCancer.
Genomeweb – Nov. 14
In addition to Vanderbilt, survey partners represented the Veterans Affairs Salt Lake City Health Care System, Indiana University, and the H. Lee Moffitt Cancer Center in Tampa, Florida.
Naples News – Nov. 14
That never happened, so Dixon was taken to Tampa's Moffitt Cancer Center, where he underwent chemotherapy so strong that it gutted his mouth. With nine teeth gone, Dixon could barely eat and the weight slid off.
Data Breach Today – Nov. 14
When implementing endpoint security solutions in healthcare environments, a critical consideration is the impact of the technology on clinical workflow, says Dave Summitt, CISO at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. Also posted to Healthcare InfoSecurity.
Photonics Media – Nov. 13
Robert Gillies, chair of the cancer physiology department and vice chair of radiology research at Moffitt Cancer Center, was awarded the 2018 Gold Medal Award by the World Molecular Imaging Society.
Mercola – Nov. 12
According to Robert Gillies, who has studied tumor formation and acidity at the Moffitt Cancer Center, 25 tumors make their own acidity by their very nature, and they do this even in an alkaline cellular structure.
The ASCO Post – Nov. 10
“Midlife PSA predicts subsequent development of aggressive prostate cancer better than either family history or race,” said co–first author and Moffitt Cancer Center epidemiologist Travis Gerke, ScD.
Bay News 9 – Nov. 8
“For decades we’ve been trying to find the right tool. Chest x-rays aren’t good enough. They are one dimensional and don’t provide enough resolution. And so chest CTs are really a three dimensional x-ray of the chest.” – Dr. Viswam Nair of Moffitt Cancer Center
WTSP – Nov. 9
Floyd Cook knows pretty much every inch of Moffitt Cancer Center. He once spent 18 straight days there under doctor care.
WTSP – Nov. 9
Weeks after surgery, Cook will be Moffitt Cancer Center's guest of honor at its third annual Veterans Day celebration on Friday. Jessica Schwarzkopf, a breast cancer survivor and daughter of the late Gen. Norman Schwarzkopf, will present Cook with a plaque to recognize him for his service.
Washington Blade – Nov. 10
The training program, OncoZine reports, was developed via an interdisciplinary collaboration between investigators at the Sylvester Comprehensive Cancer Center in Miami; the H. Lee Moffitt Cancer Center and Research Institute in Tampa; and the University of Florida Cancer Center in Gainesville.
The Cancer Letter – Nov. 9
he Richard M. Schulze Family Foundation recently made a $6 million gift to Moffitt Cancer Center. The building formerly known as the Moffitt McKinley Outpatient Center has been renamed the Richard M. Schulze Family Foundation Outpatient Center in the foundation’s honor.
Time – Nov. 8
In the ovarian cancer study, Shelley Tworoger, associate director of population science at Moffitt Cancer Center, and her colleagues also analyzed data from the Nurses’ Health Study.
Managed Healthcare – Nov. 5
Costs aside, Frederick Locke, MD, a medical oncologist and translational researcher at Moffitt Cancer Center in Tampa, Florida, enthuses that, with a single infusion of CAR T cells, 83% of patients in the ZUMA-1 clinical trial for the treatment of patients with chemorefractory-aggressive B-cell non-Hodgkin lymphoma had a measureable response with Yescarta.
Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.